Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Eli Lilly's CEO David Ricks discusses the launch of diabetes and anti-obesity drugs Mounjaro and Zepbound, focusing on expanding access in emerging markets. He highlights new weight-loss drugs and ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

Eli Lilly (LLY 1.80%) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...

For the six years it took to build the Mountain Valley Pipeline, countless opponents hindered work by sitting in trees along ...

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...

Eli Lilly and Company (NYSE:LLY) is a leading multinational pharmaceutical company that develops and markets healthcare products across various therapeutic areas. Its products range from ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

Eli Lilly stock has generated fantastic returns for investors over the past five years. The company possesses many lucrative growth opportunities to ensure it remains an excellent buy in the years ...

Circular Genomics recently moved its headquarters to Lilly Gateway Labs, aiming to enhance its Alzheimer's disease ...